21
total announcements
HESTERBIO.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹1,928 Cr
P/E (TTM)
14.1
EPS (TTM)
₹160.95
52W Low
₹1,239.30
52W High
₹2,683.60
Dividend Yield
0.49%
Beta
0.43
Price / Book
5.4
Debt / Equity
53.0
Revenue (TTM)
₹327 Cr
Gross Margin
74.86%
Operating Margin
20.37%
Hester Biosciences Ltd
Hester Biosciences Ltd has received confirmation certificates for securities dematerialized or rematerialized during the quarter ended 30 September 2026, as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Hester Biosciences Ltd
Hester Biosciences Ltd has made a capital contribution of up to INR 10.50 million to SLYCE AGRI WORLD LLP, a special purpose vehicle for group captive power generation, representing 26% of the LLP's fixed capital.
Hester Biosciences Ltd
Hester Biosciences Ltd has announced the outcome of its board meeting, where it approved a capital contribution of up to INR 10.50 million to SLYCE AGRI WORLD LLP, a special purpose vehicle for group captive power generation. The investment will enable the company to enter into a power purchase agreement and supply electricity on a captive basis.
Hester Biosciences Ltd
Hester Biosciences Ltd has announced the closure of its trading window for dealing in equity shares from 1 October 2026, until 48 hours after the release of its financial results for the quarter and six months period ended 30 September 2026.
Hester Biosciences Ltd
Hester Biosciences Ltd has announced that its shareholders have approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from Promoter and Promoter Group category to Public Category shareholders. The reclassification is subject to necessary approvals from statutory authorities.
Hester Biosciences Ltd
Hester Biosciences Ltd held a postal ballot process to approve the reclassification of persons forming part of the Promoter Group from 'Promoter' Shareholder to 'Public' Shareholder. The resolution was passed with 99.99% assent and 0.01% dissent.
Hester Biosciences Ltd
Hester Biosciences Ltd has announced the outcome of its postal ballot process, where shareholders approved the reclassification of persons forming part of the Promoter Group from 'Promoter' Shareholder to 'Public' Shareholder. The resolution was passed with 99.99% assent and 0.01% dissent.
Hester Biosciences Ltd
Hester Biosciences Ltd has announced an upgrade in credit ratings by CARE Ratings Limited, with the long-term bank facilities rating upgraded from CARE BBB; Stable to CARE BBB+; Stable, and the short-term bank facilities rating upgraded from CARE A3+ to CARE A2.
Hester Biosciences Ltd
Hester Biosciences Ltd has announced a Postal Ballot Notice to reclassify persons forming part of the Promoter Group from 'Promoter' Shareholder to 'Public' Shareholder.
Hester Biosciences Ltd
Hester Biosciences Ltd reported Q1 FY27 earnings with 14% revenue growth and 88% PAT increase. Gross margins improved to 78% and EBITDA grew by 95%. The company's Poultry Healthcare Division recorded 48% growth, while the Animal Healthcare Division was impacted by timing of government-led immunization programs.
Hester Biosciences Ltd
Hester Biosciences Ltd has launched an interactive microsite for its 39th Annual Report FY 2025-26, providing a digital and accessible format for stakeholders to view key financial, operational, and strategic highlights.
Hester Biosciences Ltd
Hester Biosciences Ltd has published the extract of consolidated unaudited financial results for the quarter ended 30 June 2026 in the Ahmedabad edition of Financial Express.
Hester Biosciences Ltd
Hester Biosciences Ltd has made the audio recording of its earnings conference call for the quarter ended 30 June 2026 available on its website.
Hester Biosciences Ltd
Hester Biosciences Ltd announced its unaudited financial results for Q1 FY27, with standalone revenue up 14% and profit up 88%, and consolidated revenue down 8% and profit up 459% due to an exceptional gain from the amendment of the Gates Foundation loan.
Hester Biosciences Ltd
Hester Biosciences Ltd has announced its financial results for the quarter ended 30 June 2026, with a profit of INR 147.11 crore and a total comprehensive income of INR 147.11 crore. The company's revenue from operations was INR 726.60 crore, with a segment-wise revenue of INR 18.16 crore from Poultry Healthcare and INR 108.44 crore from Animal Healthcare. The company's segment results were INR 236.72 crore, with a profit before tax of INR 197.52 crore.
Hester Biosciences Ltd
Hester Biosciences Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended 30 June 2026. The company's revenue from operations was INR 26.60 crore, with a net profit of INR 147.11 crore. The results were approved by the Board of Directors in a meeting held on 30 July 2026.
Hester Biosciences Ltd
Hester Biosciences Ltd has scheduled an earnings conference call on July 30, 2026, to discuss Q1FY27 results. The call will be represented by the CEO, Executive Director, and CFO.
Hester Biosciences Ltd
Hester Biosciences Ltd has received NOC from NSE and BSE for the re-classification of Mr. Ravin Gandhi and Ms. Bela Gandhi from Promoter Group to Public category.
Hester Biosciences Ltd
Hester Biosciences Ltd has scheduled a Board meeting on 30/07/2026 to consider the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.
Hester Biosciences Ltd
Hester Biosciences Ltd has announced the voting results of its 39th Annual General Meeting, where all resolutions were passed with the requisite majority. The company received 100% votes in favor of Resolution No. 1 and 99.79% in favor of Resolution No. 6.